comparemela.com
Home
Live Updates
Host Webcast Investor Call - Breaking News
Pages:
Latest Breaking News On - Host webcast investor call - Page 1 : comparemela.com
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor
United-states
Puerto-rico
Singapore
America
American
Davidp-carbone
Laurie-fenton-ambrose
Murdo-gordon
Jay-bradner
Justin-claeys
Linkedin
Teneobio-inc
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
/PRNewswire/ Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRAâ„¢ (tarlatamab-dlle) for the.
Puerto-rico
Singapore
United-states
America
American
Justin-claeys
Jay-bradner
Davidp-carbone
Laurie-fenton-ambrose
Murdo-gordon
Instagram
World-most-innovative-companies
vimarsana © 2020. All Rights Reserved.